Key Facts
• July 25: Manufacturer Denka halts tetanus vaccine shipments due to production concerns.
• Tetanus bacteria enter through wounds, causing paralysis and potentially death.
• Symptoms include difficulty swallowing and inability to lift ankles.
• Tetanus vaccine prevents severe cases; annual infections dropped from 1,000 to 100.
• Denka’s vaccine supply accounts for a significant domestic share.
• Hospitals like Meitetsu Hospital report only two months of vaccine stock left.
• Common tetanus risks: rusty nails, animal bites, deep wounds, and accidents.
• Doctors urge caution during outdoor activities to avoid injuries.
• Denka is working to resume vaccine production but has no timeline.
• Without vaccines, hospitals fear a rise in tetanus cases.
Summary
The sudden halt in tetanus vaccine shipments by major manufacturer Denka has raised concerns among medical professionals. Tetanus, a potentially fatal disease caused by bacteria entering through wounds, can lead to severe symptoms like muscle paralysis and difficulty swallowing. Vaccines have significantly reduced annual cases from 1,000 to around 100, but hospitals now face shortages, with some reporting only two months of supply remaining. Denka cited production process issues as the reason for the suspension and is working to resume supply. Doctors emphasize the importance of avoiding injuries, particularly during outdoor activities, to prevent tetanus infections. The situation highlights the critical role of vaccines in public health.
